IMBECU   20882
INSTITUTO DE MEDICINA Y BIOLOGIA EXPERIMENTAL DE CUYO
Unidad Ejecutora - UE
artículos
Título:
VITAMIN D-MITOCHONDRIA CROSS-TALK COULD MODULATE THE SIGNALING PATHWAY INVOLVED IN HYPERTENSION DEVELOPMENT: A TRANSLATIONAL INTEGRATIVE OVERVIEW
Autor/es:
NICOLÁS SANTINO; LUCIANA MAZZEI; WALTER MANUCHA; RAÚL SANZ; MARCO INGRASIA
Revista:
Clínica e Investigación en Aterosclerosis
Editorial:
Barcelona : Ediciones Doyma S.A.
Referencias:
Lugar: Barcelona; Año: 2020 vol. 32 p. 144 - 155
Resumen:
Vitamin D deficiency is a worldwide pandemic and results in osteoporosis, hypertension, and other cardiovascular diseases. At the cellular level, it produces significant oxidative stress, inflammatory markers, and mitochondrial damage. There is increasing evidence about the role of vitamin D in the regulation of the renin-angiotensin-aldosterone system (RASS). Moreover, the evidence involves cardiovascular complications, as well as the immune system disorders. Vitamin D values below 25ng/mL are related to an increase in vascular tone mediated by smooth muscle contraction. Also, it can produce direct effects on vascular smooth muscle cells, RASS overregulation, modulation of calcium metabolism, and secondary hyperparathyroidism; which predisposes patients to develop hypertrophy of the left ventricle and vascular wall causing hypertension. In this work, we reviewed the main mechanisms involved in the development of hypertension due to vitamin D deficiency. Among them, the link established between the levels of extramitochondrial inorganic phosphate, its main regulatory hormones -such as vitamin D-, the cardiovascular system, reactive oxygen species, and mitochondrial metabolism. The role of the mitochondrial vitamin D receptor and the regulation of the respiratory chain would influence arterial remodeling since its activation would reduce oxidative damage and preserve cell life. However, there are aspects not yet understood about the intricate signaling network that was simple in experimental trials, but complex in clinical studies. In this way, the completion of new studies as VITAL, could clarify and thus support or refute the possible benefits of Vitamin D in hypertensive cardiovascular disease.